Impact of Eslicarbazepine Acetate on Lipid Metabolism and Cardiovascular Risk Factors

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02573272

Enrollment

204

Registered

2015-10-09

Start date

2015-06-30

Completion date

2016-10-31

Last updated

2015-10-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Epilepsy

Brief summary

Knowing the impact that the use of ESL as adjunctive treatment of partial epilepsy has on cardiovascular risk factors measured by biochemical and ultrasound parameters compared with enzyme-inducing AEDs.

Interventions

DRUGeslicarbacepine

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients over 18 years * patients definitively diagnosed Focal Epilepsy based on clinical criteria and additional tests. * patients with stable and identifiable antiepileptic treatment during the last two years. * patients according to the investigator are able to provide clinical data necessary for the development of the study * Patients who signed informed consent

Exclusion criteria

* Patients who, according to their evolution and demands of clinical practice, their previous treatment has to be changed for this reason breach inclusion criteria and / or attachment to one of the study groups.

Design outcomes

Primary

Measure	Time frame
Carotid IMT millimeters	one year

Countries

Spain

Contacts

Primary ContactMaría del Mar Benjumea

maria.benjumea@juntadeandalucia.es955 040 460

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026